Karyopharm completes patient recruitment in phase 3 siendo study of selinexor in patients with endometrial cancer

Newton, mass., dec. 2, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the completion of patient recruitment in the phase 3 siendo study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer.
KPTI Ratings Summary
KPTI Quant Ranking